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Edited by Lukas HuberAbstract We examined the inﬂuence of S-nitrosoglutathione
(GSNO) on aIIbb3 integrin-mediated platelet adhesion to immo-
bilised ﬁbrinogen. GSNO induced a time- and concentration-
dependent inhibition of platelet adhesion. Inhibition was
cGMP-independent and associated with both reduced platelet
spreading and protein tyrosine phosphorylation. To investigate
the cGMP-independent eﬀects of NO we evaluated integrin b3
phosphorylation. Adhesion to ﬁbrinogen induced rapid phosphor-
ylation of b3 on tyrosines 773 and 785, which was reduced by
GSNO in a cGMP independent manner. Similar results were ob-
served in suspended platelets indicating that NO-induced eﬀects
were independent of spreading-induced signalling. This is the ﬁrst
demonstration that NO directly regulates integrin b3 phosphory-
lation.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Nitric oxide; Platelets; cGMP; Integrin aIIbb3;
Tyrosine phosphorylation1. Introduction
The integrin aIIbb3 mediates platelet adhesion to immobi-
lised ﬁbrinogen. aIIbb3 is found on the platelet surface in a
cryptic low aﬃnity form, but upon inside-out signalling in-
duced by platelet agonists, it is converted to its high aﬃnity
form capable of ligand binding. aIIbb3 is targeted by intracellu-
lar signalling cascades, but can also initiate outside-in signal-
ling. Signalling through aIIbb3 results in activation of protein
tyrosine phosphorylation signalling events and determines
the extent of platelet spreading on von Willebrand Factor or
ﬁbrinogen surfaces and their resistance to detachment [1,2].
The cytoplasmic tail of the b-integrin is considered critical to
integrin-mediated platelet spreading through interactions with
the cytoskeleton [3,4]. Ligand-induced phosphorylation of b3-
integrin leads to its interaction with signalling proteins such as
the Src family kinases, Syk, protein kinase C, phospholipase
Cc2 and with structural cytoskeletal proteins such as a-actinin
and talin [2–5]. Although a model for the activation of outside-*Corresponding author. Fax: +44 1274 309742.
E-mail address: k.m.naseem@bradford.ac.uk (K.M. Naseem).
0014-5793/$32.00  2007 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2007.02.072in signalling pathways is emerging, little is known of the neg-
ative regulation of integrin signalling.
Nitric oxide (NO) acts to both inhibit platelet adhesion to
the extra cellular matrix (ECM) and limit platelet aggregation
[6,7]. NO blunts agonist-induced biochemical signalling in sus-
pended platelets leading to reduced integrin activation, Ca2+
mobilisation, secretion and thromboxane A2 (TxA2) release
[8]. While it is established that NO inhibits inside-out signal-
ling and aIIbb3 activation induced by agonists [9], it is unclear
if NO inhibits outside-in signalling mediated through b3 phos-
phorylation. We examined the eﬀects of NO on outside-in sig-
nalling using platelet adhesion and b3 phosphorylation as
markers of integrin function. Our data demonstrate that NO
reduces integrin-mediated signalling in a cGMP-independent
manner, via modulation of b3 phosphorylation suggesting a
novel mechanism of NO action in platelet signalling.2. Materials and methods
2.1. Materials
The antibodies used were anti-phosphotyrosine monoclonal anti-
body (MoAb) 4G10 (Upstate Biotechnology Inc., Milton Keynes,
UK), anti-Syk mouse MoAb (Santa Cruz, Herts., UK), phospho-Ser
239 VASP and anti-integrin b3 antibodies (Cell Signalling Technology,
Hitchin, UK), phospho-Tyr 773 phospho-Tyr 785 integrin b3 (Bio-
source Intern., CA, USA), anti-mouse and anti-rabbit IgG HRP
(Amersham Biosciences, Bucks., UK). DC protein assay kit was pur-
chased from Bio-Rad (Hemel-Hempstead, Herts., UK). 1H-[1,2,4]-
Oxadiazolo [4, 3-a]-quinoxalin-1-one (ODQ) was obtained from
Calbiochem (Nottingham, UK). All other reagents were from Sigma
Ltd (Poole, UK).
2.2. Platelet preparation
Human blood was taken from drug-free volunteers using acid citrate
dextrose (29.9 mM Na citrate, 113.8 mM glucose, 72.6 mM NaCl and
2.9 mM citric acid, pH 6.4) as anticoagulant. Washed platelets were
prepared by the prostaglandin method [10] and were incubated with
ayprase and indomethacin (10 lM) to abrogate the eﬀects of ADP,
and T · A2 respectively.2.3. Platelet adhesion assay
96-well micro titre plates were coated using ﬁbrinogen (1 mg/ml) or
heat-inactivated human serum (HS) for 24 h at 4 C and blocked with
HS (5%) diluted in PBS. Platelets were incubated with inhibitors for
the required time and then allowed to adhere at 37 C for the indicated
time. Non-adherent platelets were removed and adherent platelets were
incubated with 0.1 M citrate buﬀer containing 5 mM p-nitrophenol
phosphate and 0.1% Triton X-100 (31 mM citric acid, 5 mM sodium
citrate dehydrate, 5 mM p-nitrophenyl phosphate, 0.1% (v/v) Tritonation of European Biochemical Societies.
Fig. 1. Platelet adhesion in the absence of exogenous agonists and
secondary mediators. (A) Washed platelets (1 · 108 platelets/ml) were
suspended in Mg2+-free or Mg2+ (1 mM)-replete Tyrode’s buﬀer were
adhered to ﬁbrinogen (1 mg/ml) coated 96-well plates. Platelets were
incubated for 15 min at 37 C in the presence of apyrase (1U/ml),
indomethacin (10 lM), and RGDS (2 mM) as indicated. Adhesion was
measured spectrophotometrically as described in experimental proce-
dures. Results are presented as means ± S.E.M. of ﬁve independent
experiments each performed in triplicate. (**P 6 0.001 compared to no
1530 N.G. Oberprieler et al. / FEBS Letters 581 (2007) 1529–1534X-100, pH 5.4) for 1 h at room temperature. The reaction product was
visualised using 2 N NaOH at 405 nm [11]. None of the platelet re-
agents used had any eﬀect on platelet acid phosphatase activity (not
shown).
2.4. Microscopy
Platelets (2 · 107/ml) were adhered to ﬁbrinogen (1 mg/ml)-coated
coverslips for 30 min at 37 C. In the presence and absence of GSNO
(100 lM). Non-adherent platelets were removed, and adherent plate-
lets were ﬁxed with 4% paraformaldehyde and permeablised with
0.1% Triton-X-100. Platelets were stained for F-actin using tetrameth-
ylrhodamine isothiocyanate (TRITC)-conjugated phalloidin and visu-
alised using Fluorescent microscope (Nikon Eclipse 80i). For each
experiment, the number of platelets from eight random ﬁelds of view
were added and the results calculated as mean number of adherent
platelet ± S.E.M. per 0.1 mm2.
2.5. Immunoblotting studies
Platelets (5 · 108/ml) were adhered to ﬁbrinogen (1 mg/ml)-coated
wells (six-well plates) in the presence or absence of GSNO for up to
60 min. Non-adherent platelets were removed and adherent platelets
lysed by the addition of Laemmli sample buﬀer (1·). For VASP studies
both adherent and non-adherent platelets were immunoblotted. After
accounting for ﬁbrinogen, lysate protein (20 lg) was subjected to
SDS–PAGE (10–18%) and then transferred to polyvinylidene
diﬂuoride (PVDF) membranes. Membranes were probed with either
anti-phosphotyrosine 4G10 (1:1000), anti-phospho-b3Y
773, anti-phos-
pho-b3Y
785 (1:1000) or anti phosphoserine239 VASP (1:1000), and
stripped and reprobed with either anti-Syk (1:2000), anti-b3 or anti-
VASP. All antibodies were diluted in TBS-T containing 2% BSAMem-
branes were visualised with enhanced chemiluminescence (ECL).
Densitometric analyses were performed using Scion Image program
(NIH), and expressed as a ratio of phosphotyrosine to total Syk or
total b3. Protein concentrations were determined in platelet lysates using
the BioRad protein assay using bovine serum albumin as standard.
2.6. Statistical analysis
Results are expressed as means ± S.E.M. and were analysed using
the Student’s t-test or ANOVA for unpaired data as appropriate.
The results were considered signiﬁcant when P values were <0.05.Mg2+; ##P 6 0.001 compared to the absence of RGDS). (B) Washed
platelets were prepared as in (A) and left to adhere for 15, 30, and
60 min (*P < 0.05 compared to 15 min). Adhesion in the presence of
1 mM Mg2+ after 15 min was regarded as 100%.3. Results
3.1. The eﬀect of exogenous NO on integrin aIIbb3-mediated
platelet adhesion
Incubation of platelets in ﬁbrinogen coated wells in the ab-
sence of platelets agonists led to a signiﬁcant increase in platelet
adhesion. This response was aIIbb3-dependent since preincuba-
tion of platelets with Arg-Gly-Asp-Ser peptide (RDGS; 2 mM),
an aIIbb3 peptide blocker, ablated adhesion (P < 0.001; Fig. 1).
Incubation with GSNO led to a concentration-dependent inhi-
bition of platelet adhesion to immobilised ﬁbrinogen (ANOVA:
P 6 0.001) (Fig. 2A). After 15 min, adhesion was inhibited by
16.5 ± 8.4% (P 6 0.05) using 1 lMGSNO, and maximal eﬀects
observed at 100 lM GSNO (41.5 ± 4.6%, P 6 0.001) (Fig. 2A,
black ﬁll). Similar results were obtained with a structurally dis-
tinct NO donor, DPTA-NONOate, while NO-depleted GSNO
had no eﬀect (not shown).
GSNO inhibits platelet aggregation through cGMP-depen-
dent and independent mechanisms [12,13], however it is un-
known if the same is true for integrin-driven adhesion. To
address this issue we used the soluble guanylyl cyclase
(sGC) inhibitor ODQ [14]. GSNO (100 lM) inhibited platelet
adhesion by 41.5 ± 4.6%, which surprisingly was unaﬀected by
the presence ODQ (20 lM) (43.8 ± 5.2% Fig. 2A), suggesting
that integrin aIibb3-mediated outside-in signalling and adhe-
sion is inhibited by GSNO in a sGC-independent manner.ODQ ablated NO-induced sGC activity as evidenced by the
inhibition of VASP phosphorylation at serine239, as a marker
of the NO/sGC/Protein kinase G (PKG) signalling pathway
[15]. Furthermore, ODQ completely inhibited GSNO-induced
cGMP formation in suspended platelets (not shown). Thus,
NO-mediated inhibition of adhesion under these conditions
occurs via a cGMP-independent mechanism. The platelet
adhesion assay results were conﬁrmed by staining of the actin
cytoskeleton using TRITC-labelled phalloidin. Platelets ad-
hered to ﬁbrinogen and underwent the full range of morpho-
logical changes from ﬁlopodia formation to full spreading
(Fig. 2C and D). The number of platelets forming stable
adhesions on ﬁbrinogen was 182 ± 12 per 0.1 mm2, which
was reduced to 114.0 ± 1 platelets/0.1 mm2 in the presence
of GSNO(10 lM) (Fig. 2C and D), representing a 36% reduc-
tion in platelet adhesion (P 6 0.01). Furthermore, GSNO was
able to inhibit the ability of adherent platelets to spread
(Fig. 2D).
3.2. Eﬀect of NO on integrin aIIbb3-mediated outside-in
signalling
b3 phosphorylation is critical to facilitating the platelet adhe-
sion response through initiation of signalling cascades that
Fig. 2. NO-mediated inhibition of adhesion to immobilised ﬁbrinogen. (A) Washed platelets (1 · 108 platelets/ml) were preincubated for 10 min with
GSNO (0–100 lM), and ODQ (20 lM) as indicated, and allowed to adhere to ﬁbrinogen-coated wells at 37 C for 15 min (**P < 0.001 compared to
no GSNO treatment). (B) Washed platelets (5 · 108 platelets/ml) were preincubated with GSNO and added to ﬁbrinogen-coated wells (6-well plates)
in the presence and absence of ODQ (20 lM) for up to 30 min. Cells were lysed, separated by SDS–PAGE and immunoblotted for phosphoVASP-
serine239 and reprobed for b-tubulin. The blot is representative of three independent experiments. (C) and (D) Platelets were adhered to ﬁbrinogen-
coated coverslips for 15 min at 37 C in absence (C) and presence (D) of GSNO (100 lM). Adherent platelets were stained for F-actin with
TRITC-conjugated phalloidin. The data are then expressed as means ± S.E.M. of three number of adherent per 0.1 mm2 independent experiments
performed in duplicate (*P 6 0.05).
Fig. 3. NO reduces adhesion induced tyrosine phosphorylation of
platelet proteins. (A) Washed platelets (5 · 108 platelets/ml) were
adhered to ﬁbrinogen-coated wells (6-well plates) in the presence and
absence of GSNO (100 lM) for up to 60 min at 37 C. In control
experiments platelets were also incubated in wells coated with heat-
inactivated human serum (HS). At the appropriate times, cells were
lysed, the lysate proteins were separated by SDS–PAGE (10–18%) and
immunoblotted for phosphotyrosine. The blot shown is representative
of three independent experiments. (B) Densitometry measurement of
the 90 kDa band expressed as ratio of pY/total Syk and presented as
means ± S.E.M. of three independent experiments (*P 6 0.05).
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adhesion to immobilised ﬁbrinogen for 15 min induced tyro-
sine phosphorylation in a number of proteins, with robust
phosphorylation observed in proteins apparent molecular
weights of approximately 125 kDa, 90 kDa, 72 kDa 55 kDa
and 39 kDa (Fig. 3A). Beyond this time point adhesion in-
duced tyrosine phosphorylation decreased (Fig. 3B). In the
presence of GSNO tyrosine phosphorylation of a number of
proteins was inhibited, with the most notable reduction was
observed at 15mins with the 90 kDa protein band (P 6 0.05;
Fig. 3B).
3.3. Eﬀect of NO on individual integrinb3phosphorylation sites
The integrin b3 becomes phosphorylated on tyrosine
773 and
tyrosine785 (human sequence) in response to ligand binding
[18] (Fig. 4A). Since the 90 kDa phosphoprotein could repre-
sent integrin b3 (Fig. 4A), we investigated whether both resi-
dues become phosphorylated during platelet adhesion and
whether NO exhibits its inhibitory eﬀect in a tyrosine residue
speciﬁc manner. Immunoblotting of proteins from adherent
platelets or suspended platelets treated with ﬁbrinogen demon-
strated increased phosphorylation of tyrosine773/783 (Fig. 4B),
which was inhibited signiﬁcantly by GSNO (100 lM)
(P 6 0.05). Since NO inhibits platelet adhesion and spreading,
the reduced tyrosine phosphorylation of b3 may represent a re-
duced spreading induced signalling. To obviate spreading in-
duced signalling the experiments were repeated in suspended
platelets using soluble ﬁbrinogen (250 lg/ml) in the presence
of 1 mM Mn2+ [16]. Under these conditions b3 phosphoryla-
tion at tyrosine773/783 was increased and consistent with adhe-
sion experiments was inhibited signiﬁcantly by GSNO
(100 lM) (Fig. 4C). When platelets were exposed to NO
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phosphorylation of the integrin remained inhibited (Fig. 4D,
lanes 1 and 4).4. Discussion
Platelet adhesion and spreading on immobilised ﬁbrinogen
occurs in the absence of exogenously added platelet agonists
[19]. We used this phenomenon to study the eﬀects NO on inte-
grin signalling. NO induced a sustained inhibition of adhesion,
which was concentration dependent, but also reduced platelet
spreading on ﬁbrinogen. Platelet spreading is required for sta-Fig. 4. Eﬀect of NO on phosphorylation of cytoplasmic tyrosine residues
incubated with in the presence (lane 2) and absence (lane 1) ﬁbrinogen (250
platelets/ml) were adhered to ﬁbrinogen-coated wells (6-well plates) in the pre
(3 · 108 platelets/ml) were incubated with ﬁbrinogen (250 lg/ml) in the presen
(A). (D) Platelets were treated as in (C) except that in some cases the platelets
Laemmli buﬀer and after normalisation of protein content, the lysate pr
phosphotyrosine, phospho-b3Y
773, and phospho-b3Y
785. Membranes wer
Densitometry analysis was conducted on integrin b3-pY
773, integrin b3-pY
785,
independent experiments expressed as percentage change, calculated using th
NO treatment was considered 100% (*P 6 0.05 and **P 6 0.001 compared tble adhesion and it is possible that NO blocks spreading lead-
ing to reduced adhesion. Interestingly complete inhibition of
adhesion was never attained regardless of time of incubation
or concentration of NO used. Thus, a signiﬁcant proportion
of the adhesion response to immobilised ﬁbrinogen is resistant
to NO even at high concentrations. The reasons for this are un-
clear since GSNO at these concentrations completely inhibits
agonist-induced aggregation and ﬁbrinogen binding [9,20].
These high concentrations of NO are associated with cGMP
independent eﬀects on platelets. Certainly the kinetics of the
adhesion assay would suggest that cGMP levels, which peak
approximately 1 min after exposure to NO [21], would have
return to basal before signiﬁcant adhesion had taken placein adherent platelets. (A) Washed platelets (3 · 108 platelets/ml) were
lg/ml)/Mn2+ (1 mM) 37 C for 15 min. (B) Washed platelets (5 · 108
sence and absence of GSNO for 15 min at 37 C. (C) Washed platelets
ce of 1 mMMn2+ 37 C for 15 min. Cells were lysed and processed as in
were preincubated with ODQ (20 lM). In all cases cells were lysed with
oteins were separated by SDS–PAGE (10–18%) immunoblotted for
e subsequently stripped and reprobed with a total b3 antibody.
and total integrin b3-pY. Results represent the means ± S.E.M. of four
e ratio of the according pY/total b3. Ratio obtained in the absence of
o no GSNO treatment).
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iated platelet adhesion was cGMP-independent despite activa-
tion of the PKG signalling pathway. It is possible that cGMP
signalling is important for short term regulation of platelets,
but prolonged inhibition is mediated by cGMP-independent
mechanisms. Furthermore adhesion-induced (outside-in) sig-
nalling generated by adherent platelets under static conditions
is more resistant to the actions of NO, whether they are
cGMP-dependent or independent, compared to stimulation
of platelets in suspension.
Platelet adhesion and spreading on ﬁbrinogen activates pro-
tein tyrosine phosphorylation signalling cascades [5,22]. We
observed robust phosphorylation of proteins of apparent
molecular weights of 125 kDa, 90 kDa, 72 kDa, 55 kDa and
39 kDa. Interestingly NO speciﬁcally reduced phosphorylation
of the 90 kDa protein band. Since b3integrin has an apparent
molecular weight of 90 kDa, we tested the eﬀects of NO on
b3 phosphorylation. Platelet adhesion was associated with b3
phosphorylation on two residues, tyrosine 773 and 785. Impor-
tantly the level of phosphorylation was reduced by the pres-
ence of GSNO. Importantly, GSNO also inhibited tyrosine
phosphorylation of b3 induced by soluble ﬁbrinogen in the
presence of Mn2+, indicating that NO inhibited phosphoryla-
tion directly by reducing spreading-induced signalling. Thus,
NO inhibits b3 phosphorylation, which is associated with a re-
duced adhesion and spreading response.
The precise cGMP-independent mechanism by which NO
regulates integrin function remains elusive. Possible mecha-
nisms of action for NO, independent of soluble guanylyl cy-
clase include protein S-nitrosylation and nitration. The
integrin aIIbb3 has an extracellular cysteine-rich domain in
the b3 subunit that includes a number of unpaired cysteines.
Rearrangement of disulﬁde bonds in an enzyme dependent
process is required in order to allow ﬁbrinogen binding to
the integrin [23–25]. NO can induce S-nitrosylation of cysteine
residues in a number of proteins leading to altered function. S-
nitrosylation of b3 by NO would prevent sulfhydryl rearrange-
ment within the integrin and render the integrin either unable
to engage with ﬁbrinogen eﬀectively or aﬀect its ability to
transduce signals. An alternative mechanism may involve pro-
tein disulphide isomerase (PDI), an enzyme that rearranges
disulphide bonds, which is present on the platelet surface
and has been implicated in facilitating integrin activation
[23]. A recent study by Uehara et al. demonstrated the inhibi-
tion of PDI by S-nitrosylation in cerebrocortical neurons [26].
If NO inhibits platelet PDI this could result in failure to facil-
itate integrin activation. Certainly a mechanism involving S-
nitrosylation is consistent with the higher concentrations of
NO required in inhibit integrin function, since sGC activation
occurs at much lower concentrations [27]. In conclusion our
data demonstrate for the ﬁrst time that NO inhibits b3 phos-
phorylation, integrin-mediated outside-in signalling leading
to reduced platelet adhesion, in a cGMP-independent manner.
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